IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors
BackgroundInterferon-inducible protein-10 (IP-10) and monokine induced by interferon-gamma (MIG) are chemokines recognized as inflammatory biomarkers during HIV-1 infection. We assessed their early and long-term dynamics after initiation of antiretroviral treatment (ART).MethodsPersons with HIV-1 (P...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1257725/full |
| _version_ | 1797657093393612800 |
|---|---|
| author | Hortensia Álvarez Hortensia Álvarez Alicia Gutiérrez-Valencia Ana Mariño Abraham Saborido-Alconchel Beatriz Calderón-Cruz Alexandre Pérez-González Jacobo Alonso-Domínguez Inés Martínez-Barros María Gallego-Rodríguez Santiago Moreno Teresa Aldamiz Marta Montero-Alonso Enrique Bernal Carlos Galera Josep M. Llibre Eva Poveda |
| author_facet | Hortensia Álvarez Hortensia Álvarez Alicia Gutiérrez-Valencia Ana Mariño Abraham Saborido-Alconchel Beatriz Calderón-Cruz Alexandre Pérez-González Jacobo Alonso-Domínguez Inés Martínez-Barros María Gallego-Rodríguez Santiago Moreno Teresa Aldamiz Marta Montero-Alonso Enrique Bernal Carlos Galera Josep M. Llibre Eva Poveda |
| author_sort | Hortensia Álvarez |
| collection | DOAJ |
| description | BackgroundInterferon-inducible protein-10 (IP-10) and monokine induced by interferon-gamma (MIG) are chemokines recognized as inflammatory biomarkers during HIV-1 infection. We assessed their early and long-term dynamics after initiation of antiretroviral treatment (ART).MethodsPersons with HIV-1 (PWH) aged>18 years starting their first ART in 2015-2021 in a prospective cohort (n=73) were included. IP-10 and MIG plasma levels were quantified using a multiplexed bead-based assay.ResultsIP-10 and MIG plasma levels showed a significant and consistent reduction following ART (80% integrase inhibitor [INSTI]-based) initiation, starting at day 20 and maintained throughout the study period (48 months), paralleling the HIV-1 RNA decay and CD4+ count recovery (p<0·001). At baseline, PWH≥ 50 years, CDC stage C and CD4+ count<350cells/mm3 had higher levels of IP-10 (p=0·022, p=0·001 and p=0·002, respectively) and MIG (p<0·001, p=0·024 and p=0·069, respectively). All of them matched their counterparts several months following ART initiation. MIG levels showed a greater decrease at day 10 in those treated with INSTI (p=0·038). Low-level HIV-1 viremia did not impact MIG or IP-10 levels.ConclusionPlasma IP-10 and MIG showed an early significant decline following ART initiation, with greater early declines in MIG levels in INSTI-based regimens. These findings suggest a strong impact of HIV-1 viremia on IP-10 and MIG levels. |
| first_indexed | 2024-03-11T17:39:24Z |
| format | Article |
| id | doaj.art-05dbdc4966774d298769b1f9a2969dfe |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T17:39:24Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-05dbdc4966774d298769b1f9a2969dfe2023-10-18T12:26:33ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-10-011410.3389/fimmu.2023.12577251257725IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitorsHortensia Álvarez0Hortensia Álvarez1Alicia Gutiérrez-Valencia2Ana Mariño3Abraham Saborido-Alconchel4Beatriz Calderón-Cruz5Alexandre Pérez-González6Jacobo Alonso-Domínguez7Inés Martínez-Barros8María Gallego-Rodríguez9Santiago Moreno10Teresa Aldamiz11Marta Montero-Alonso12Enrique Bernal13Carlos Galera14Josep M. Llibre15Eva Poveda16Infectious Diseases Unit, Department of Internal Medicine, Complexo Hospitalario Universitario de Ferrol, Servicio Galego de Saúde (SERGAS)-A Coruña, A Coruña, SpainDepartment of Biochemistry, Genetics and Immunology, Universidade de Vigo, Vigo, SpainClinical Unit of Infectious Diseases and Microbiology, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, Spanish National Research Council (CSIC), University of Seville, Seville, SpainInfectious Diseases Unit, Department of Internal Medicine, Complexo Hospitalario Universitario de Ferrol, Servicio Galego de Saúde (SERGAS)-A Coruña, A Coruña, SpainClinical Unit of Infectious Diseases and Microbiology, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, Spanish National Research Council (CSIC), University of Seville, Seville, SpainGalicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, Servicio Galego de Saúde-Universidade de Vigo (SERGAS-U, Vigo), Vigo, SpainGalicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, Servicio Galego de Saúde-Universidade de Vigo (SERGAS-U, Vigo), Vigo, SpainGalicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, Servicio Galego de Saúde-Universidade de Vigo (SERGAS-U, Vigo), Vigo, SpainGalicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, Servicio Galego de Saúde-Universidade de Vigo (SERGAS-U, Vigo), Vigo, SpainGalicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, Servicio Galego de Saúde-Universidade de Vigo (SERGAS-U, Vigo), Vigo, SpainInfectious Diseases Department, Hospital Universitario Ramón y Cajal, Madrid, SpainInfectious Diseases Unit, Hospital General Universitario Gregorio Marañón, Madrid, SpainInfectious Diseases Unit, Hospital Universitario y Politécnico La Fe, Valencia, SpainInfectious Diseases Unit, Hospital General Universitario Reina Sofía, Murcia, SpainInternal Medicine Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain0Infectious Diseases Division and Fight Infections Foundation, University Hospital Germans Trias i Pujol, Badalona, Barcelona, SpainGalicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, Servicio Galego de Saúde-Universidade de Vigo (SERGAS-U, Vigo), Vigo, SpainBackgroundInterferon-inducible protein-10 (IP-10) and monokine induced by interferon-gamma (MIG) are chemokines recognized as inflammatory biomarkers during HIV-1 infection. We assessed their early and long-term dynamics after initiation of antiretroviral treatment (ART).MethodsPersons with HIV-1 (PWH) aged>18 years starting their first ART in 2015-2021 in a prospective cohort (n=73) were included. IP-10 and MIG plasma levels were quantified using a multiplexed bead-based assay.ResultsIP-10 and MIG plasma levels showed a significant and consistent reduction following ART (80% integrase inhibitor [INSTI]-based) initiation, starting at day 20 and maintained throughout the study period (48 months), paralleling the HIV-1 RNA decay and CD4+ count recovery (p<0·001). At baseline, PWH≥ 50 years, CDC stage C and CD4+ count<350cells/mm3 had higher levels of IP-10 (p=0·022, p=0·001 and p=0·002, respectively) and MIG (p<0·001, p=0·024 and p=0·069, respectively). All of them matched their counterparts several months following ART initiation. MIG levels showed a greater decrease at day 10 in those treated with INSTI (p=0·038). Low-level HIV-1 viremia did not impact MIG or IP-10 levels.ConclusionPlasma IP-10 and MIG showed an early significant decline following ART initiation, with greater early declines in MIG levels in INSTI-based regimens. These findings suggest a strong impact of HIV-1 viremia on IP-10 and MIG levels.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1257725/fullantiretroviral treatmentIP-10MIGbiomarkersHIV-1 viral decay |
| spellingShingle | Hortensia Álvarez Hortensia Álvarez Alicia Gutiérrez-Valencia Ana Mariño Abraham Saborido-Alconchel Beatriz Calderón-Cruz Alexandre Pérez-González Jacobo Alonso-Domínguez Inés Martínez-Barros María Gallego-Rodríguez Santiago Moreno Teresa Aldamiz Marta Montero-Alonso Enrique Bernal Carlos Galera Josep M. Llibre Eva Poveda IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors Frontiers in Immunology antiretroviral treatment IP-10 MIG biomarkers HIV-1 viral decay |
| title | IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors |
| title_full | IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors |
| title_fullStr | IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors |
| title_full_unstemmed | IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors |
| title_short | IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors |
| title_sort | ip 10 and mig are sensitive markers of early virological response to hiv 1 integrase inhibitors |
| topic | antiretroviral treatment IP-10 MIG biomarkers HIV-1 viral decay |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1257725/full |
| work_keys_str_mv | AT hortensiaalvarez ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT hortensiaalvarez ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT aliciagutierrezvalencia ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT anamarino ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT abrahamsaboridoalconchel ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT beatrizcalderoncruz ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT alexandreperezgonzalez ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT jacoboalonsodominguez ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT inesmartinezbarros ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT mariagallegorodriguez ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT santiagomoreno ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT teresaaldamiz ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT martamonteroalonso ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT enriquebernal ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT carlosgalera ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT josepmllibre ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors AT evapoveda ip10andmigaresensitivemarkersofearlyvirologicalresponsetohiv1integraseinhibitors |